Toggle light / dark theme

When something goes wrong in mitochondria, the tiny organelles that power cells, it can cause a bewildering variety of symptoms such as poor growth, fatigue and weakness, seizures, developmental and cognitive disabilities, and vision problems. The culprit could be a defect in any of the 1,300 or so proteins that make up mitochondria, but scientists have very little idea what many of those proteins do, making it difficult to identify the faulty protein and treat the condition.

Researchers at Washington University School of Medicine in St. Louis and the University of Wisconsin–Madison systematically analyzed dozens of mitochondrial proteins of unknown function and suggested functions for many of them. Using these data as a starting point, they identified the genetic causes of three and proposed another 20 possibilities for further investigation. The findings, published May 25 in Nature, indicate that understanding how mitochondria’s hundreds of proteins work together to generate power and perform the organelles’ other functions could be a promising path to finding better ways to diagnose and treat such conditions.

“We have a parts list for mitochondria, but we don’t know what many of the parts do,” said co-senior author David J. Pagliarini, Ph.D., the Hugo F. and Ina C. Urbauer Professor and a BJC Investigator at Washington University. “It’s similar to if you had a problem with your car, and you brought it to a mechanic, and upon opening the hood they said, ‘We’ve never seen half of these parts before.’ They wouldn’t know how to fix it. This study is an attempt to define the functions of as many of those mitochondrial parts as we can so we have a better understanding of what happens when they don’t work and, ultimately, a better chance at devising therapeutics to rectify those problems.”

As they grow, solid tumors surround themselves with a thick, hard-to-penetrate wall of molecular defenses. Getting drugs past that barricade is notoriously difficult. Now, scientists at UT Southwestern have developed nanoparticles that can break down the physical barriers around tumors to reach cancer cells. Once inside, the nanoparticles release their payload: a gene editing system that alters DNA inside the tumor, blocking its growth and activating the immune system.

The new , described in Nature Nanotechnology, effectively stopped the growth and spread of ovarian and liver tumors in mice. The system offers a new path forward for the use of the gene editing tool known as CRISPR-Cas9 in , said study leader Daniel Siegwart, Ph.D., Associate Professor of Biochemistry at UT Southwestern.

“Although CRISPR offers a new approach for treating , the technology has been severely hindered by the low efficiency of delivering payloads into tumors,” said Dr. Siegwart, a member of the Harold C. Simmons Comprehensive Cancer Center.

Superhumans are coming! Various technological advances in the field of medicine through AI and CRISPR are going to radically alter our understanding of what it means to be human. AI and Crispr technology have been making revolutionary changes to the field of medicine. Artificial intelligence is being applied in identification of harmful genes and treatment of disease.

Multiple new gene editing technologies in addition to artificial intelligence will cause major changes in healthcare.
The gene-editing tool CRISPR, short for clustered regularly interspaced short palindromic repeats, could help us to reprogram life. It gives scientists more power and precision than they have ever had to alter human DNA.

Could it be conceivable that at one point in the future we could increase the average IQ of the population?
CRISPR technology in the future could enable efficient and affordable treatment of many diseases. It will be also probably used to enhance our intelligence.

CRISPR was originally designed as a technique for editing the DNA of living organisms, but its uses and capabilities have expanded substantially. It is now used widely in biomedical research, including research into human genetics. One of the main issues concerning technologies such as CRISPR-Cas9 is accuracy and safety, as mistakes can have significant and dangerous consequences when it comes to an individual’s genome.

Artificial Intelligence is touching almost every aspect of our lives. It’s reasonable to expect AI influence will only increase in the future. One of many fields heavily influenced by AI is the military. Particularly in the development of Supersoldiers. The notion of super-soldiers enhanced with biotechnology and cybernetics was once only possible in the realm of science fiction. But it may not be too long before these concepts become a reality.

A new worldwide arms race is pitting countries against each other to be the first to successfully create real genetically modified super soldiers by using tools such as CRISPR. Understandably many of these human enhancement technologies raise health and safety questions and it is more likely these enhancements will first gain traction in countries that do not place as much weight on ethical concerns.

According to US Intelligence, China has conducted “human testing” on members of the People’s Liberation Army in hope of developing soldiers with “biologically enhanced capabilities.

This has made the U.S. military’s top intelligence agencies increasingly worried but the Pentagon has significantly invested in its own research in AI and in the extension of the human senses beyond their current physical limitations, to provide soldiers with superhuman abilities.

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia, affecting more than 5.8 million individuals in the U.S. Scientists have discovered some genetic variants that increase the risk for developing Alzheimer’s; the most well-known of these for people over the age of 65 is the APOE ε4 allele. Although the association between APOE4 and increased AD risk is well-established, the mechanisms responsible for the underlying risk in human brain cell types has been unclear until now.

Researchers from Boston University School of Medicine (BUSM) have discovered two important novel aspects of the gene: 1) human genetic background inherited with APOE4 is unique to APOE4 patients and 2) the mechanistic defects due to APOE4 are unique to human cells.

Our study demonstrated what the APOE4 gene does and which brain cells get affected the most in humans by comparing human and mouse models. These are important findings as we can find therapeutics if we understand how and where this risk gene is destroying our brain.

A new theory suggests that mutations have few straightforward ways to establish themselves in cells and cause tumors.

For many researchers, the road to cancer prevention is long and difficult, but a recent study by Rice University scientists suggests that there may be shortcuts.

A theoretical framework is being developed by Rice scientist Anatoly Kolomeisky, postdoctoral researcher Hamid Teimouri, and research assistant Cade Spaulding that will explain how cancers brought on by several genetic mutations might be more readily recognized and perhaps prevented.

A long-running human trial has shown that CRISPR gene editing could prove to be a highly effective way of treating serious conditions.

The trial, which was kicked off in 2019 by an international team of scientists, found that a new gene-editing therapy called exagamglogene autotemcel, or ex-cel for short, was able to essentially “cure” patients with transfusion-dependent beta thalassemia (TDT) or severe sickle cell disease (SCD), two blood disorders that are conventionally treated using blood transfusions.

It’s a promising new use of the technology. Around 100,000 Americans are affected by TDT, while SCD affects an estimated 300 to 3,000. And in a broader sense, the results suggest that tinkering with genetic code could come to be a practical, widespread new area of medicine.

A team of researchers at the Institute of Biochemistry at Münster University discovered that by using so-called FlashCaps they were able to control the translation of mRNA by means of light. The results have been published in Nature Chemistry.

DNA () is a long chain of molecules composed of many individual components, and it forms the basis of life on Earth. The function of DNA is to store all genetic information. The translation of this into proteins—which an organism needs to function, develop and reproduce—takes place via mRNA (messenger ribonucleic acid). The DNA is transcribed to mRNA, and the mRNA in turn is translated into proteins (protein biosynthesis). In other words, the mRNA functions as an information carrier. Biochemists at the University of Münster have now developed a new biochemical tool that is able to to control the translation of RNA with the aid of light. These so-called FlashCaps enable researchers to control a variety of processes in cells both spatially and temporally and, as a result, to determine basic functions of proteins.

DNA is the basis of life on earth. The function of DNA is to store all the genetic information an organism needs to develop, function and reproduce. It is essentially a biological instruction manual found in every cell. Biochemists at the University of Münster have now developed a strategy for controlling the biological functions of DNA with the aid of light. This enables researchers to better understand and control the processes that take place in the cell—for example, epigenetics, the key chemical change and regulatory lever in DNA. The results have been published in the journal Angewandte Chemie.

The cell’s functions depend on enzymes. Enzymes are proteins that carry out in the cell. They help to synthesize metabolic products, make copies of the DNA molecules, convert energy for the cell’s activities, change DNA epigenetically and break down certain molecules. A team of researchers headed by Prof. Andrea Rentmeister from the Institute of Biochemistry at the University of Münster used a so-called enzymatic cascade reaction to understand and track these functions better. This sequence of successive reaction steps involving different enzymes makes it possible to transfer so-called photocaging groups—chemical groups that can be removed by means of irradiation with light—to DNA. Previously, studies had shown that only small residues (small modifications such as methyl groups) could be transferred selectively to DNA, RNA (ribonucleic acid) or proteins.

“As a result of our work, it is now possible to transfer larger residues or modifications such as the photocaging groups just mentioned,” explains Nils Klöcker, one of the lead authors of the study and a Ph.D. student at the Institute of Biochemistry. Working together with structural biologist Prof. Daniel Kümmel, who also works at the Institute of Biochemistry, it was also possible to explain the basis for the changed activity at a .